Verified

Pioneer SCA3 Translational Research Award

National Ataxia Foundation

The National Ataxia Foundation (NAF) is a patient-centered nonprofit organization dedicated to accelerating the development of treatments for ataxia and improving the lives of those affected by it. NAF is a global leader in driving ataxia research, fostering national and international collaboration to advance scientific discovery. As part of its commitment to identifying causes, treatments, and potential cures for ataxia, NAF offers limited, short-term financial support through its Annual Research Grant Program.

Award Overview

The NAF Pioneer SCA3 Translational Research Award is granted annually to independent researchers for outstanding proposals that aim to make meaningful advancements in the treatment and care of individuals with Spinocerebellar Ataxia Type 3 (SCA3). While proposals may include components related to other forms of ataxia, the primary focus must be on preclinical, translational or clinical research directly relevant to SCA3.

Funding Details

• Award Period: September 1, 2027 – August 31, 2028

• Award Amount: $100,000 USD

• Use of Funds:

Funds may be used for direct research expenses only. Direct research expenses refer to costs that can be specifically identified in the awarded grant to achieve progress on approved research aims. NAF supports funding for the following direct research-related expenses, subject to the requirements and limitations set forth in the NAF Annual Grant Program Policies:

o Direct salary and/or stipend costs (excluding fringe benefits) up to 50% of the award amount ($50,000 maximum), consistent with effort level and the applicable NIH salary cap or stipend level. Salary and/or stipend support from NAF and other funding sources may not exceed the applicable NIH limits or 100% compensated effort, as applicable.

o Laboratory reagents and consumable supplies

o Equipment essential to the project (not to exceed 20% of total budget)

o Animal purchase and care costs

o Costs related to publication (not to exceed $2,500 total)

o Investigator registration and travel to scientific meetings/conferences and collaboration-related site visits (not to exceed $2,000 total; economy travel only). Grantees must be presenting a poster or talk related to their active NAF award.

o Patient-related expenses directly tied to the study and not reimbursed by third-party payers, including travel

AI Based Application Success Predictor

1. Direct and substantial relevance to ataxia

Critical

A proposal should address a clearly defined question about the cause, pathogenesis, diagnosis, treatment or care of ataxia. Identify the disease or subtype, explain the unmet need and show why the findings matter specifically to ataxia. NAF states that merely incidental or tangential relevance is insufficient.

2. Strong scientific merit and methodological rigor

Critical

Present a well-supported hypothesis, appropriate models or patient populations, measurable outcomes and a convincing analysis plan. NAF's LOIs are reviewed and scored for scientific merit, and invited full applications receive multiple independent scientific reviews.

3. Potential to advance treatment development or patient care

Very high

Explain how the project could advance a therapeutic target, disease mechanism, biomarker, diagnostic method or clinically meaningful outcome. Basic research is eligible, but a clear connection between the proposed discovery and longer-term progress in ataxia strengthens the rationale.

4. Innovation and an important unanswered question

Very high

Demonstrate what is genuinely new about the biological question, technology, model or therapeutic approach. Distinguish the proposal from existing work and explain how the findings could change current understanding rather than simply reproduce known results. NAF explicitly seeks innovative, high-impact studies.

5. Exact fit with the selected funding mechanism

Very high

Match the applicant's career stage, project scope and disease focus to the award. For example, the Pioneer SCA3 award requires a predominant SCA3 focus, while the Michael Lundquist award primarily supports MSA-C. General seed funding and career-development fellowships serve different purposes.

6. Feasibility within the award period and budget

High

Most FY2027 awards fund one year of work. Define a manageable number of aims, realistic milestones, necessary resources and an achievable completion plan. A compelling project that cannot reasonably be delivered within its funding period is less persuasive.

7. Credible preliminary rationale and suitable research resources

High

Provide preliminary observations where available, relevant published evidence, access to suitable disease models or patient samples, and the expertise needed to execute the study. Pilot projects need not have every answer in advance, but the proposed experiments should be scientifically justified.

8. Potential to generate follow-on funding and sustained research

High

Show what the award will produce: proof-of-concept data, validated assays, mechanistic findings, a publication or evidence supporting a larger application. NAF explicitly expects Research Seed Money Grants to generate preliminary data for future funding.

9. Investigator potential, mentoring and research environment

High

For fellowships and early-career awards, articulate how the project develops research skills, independence and a sustained career in ataxia research. Established investigators should demonstrate the relevant expertise, facilities and collaborators. NAF's fellowship and early-career programs explicitly support researcher development.

10. Clear, compliant and persuasive application

High

Make the disease relevance, central hypothesis, innovation, expected outcomes and funding need immediately apparent in the LOI. Follow mechanism-specific formatting, eligibility and budget rules; disclose overlapping support; and submit on time. NAF allows only one LOI per applicant per funding cycle.

Specialties

Neurosciences

Eligibility Requirements

Applicants must meet the following requirements:

1. Have completed postdoctoral training and hold a full-time appointment as a faculty member, clinical fellow, or senior scientist at an academic institution, non-profit organization, or for-profit company.

2. Applications are open to U.S. and international researchers; non-U.S. citizens are eligible.

3. Prior NAF Awardees: Individuals are ineligible to apply if they received any NAF grant within the past two fiscal years, have an active NAF grant under a no-cost extension at the time of application, or are delinquent with NAF grant reporting requirements. Previous NAF Pioneer SCA3 Translational Research Award recipients are also ineligible to apply.

4. Applicants may not apply for or receive duplicate funding for their research. Applicants who have other current or pending funding must ensure that NAF Grant funds are not requested for or allocated to project aims, activities, expenses, salary support, or stipend support already funded for the same purpose by another source. All current and pending support must be disclosed to NAF as part of the application process, and applicants must notify NAF of any additional funding received during the review, pre-award, or active Grant period that may overlap with the proposed NAF-funded project.

5. Applicants may submit only one Letter of Intent to NAF per funding cycle. Applicants should select the strongest project and apply under the funding mechanism that best aligns with their career stage, eligibility, and proposed research.

Sponsor Details

Sponsor Institute/Organizations: National Ataxia Foundation

Sponsor Type: Corporate/Non-Profit

Address: 1307 2nd Ave N, Minneapolis, MN 55405

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity